Biogen (BIIB) Q4 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2025/02/12/biogen-biib-q4-2024-earnings-call-transcript/?source=iedfolrf0000001
Feb 12, 2025 - BIIB earnings call for the period ending December 31, 2024.
0
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
https://www.fool.com/investing/2024/11/26/these-are-5-worst-performing-stocks-in-the-nasdaq/?source=iedfolrf0000001
Nov 26, 2024 -
0
Biogen (BIIB) Q3 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/10/30/biogen-biib-q3-2024-earnings-call-transcript/?source=iedfolrf0000001
Oct 30, 2024 - BIIB earnings call for the period ending September 30, 2024.
0
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
https://www.zacks.com/stock/news/2332301/biogen-s-phase-ii-iii-sma-study-for-higher-spinraza-dose-meets-goals?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2332301
Sep 05, 2024 - BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
0
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
https://www.zacks.com/stock/news/2331654/denali-plans-to-file-for-accelerated-approval-of-hunter-syndrome-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2331654
Sep 04, 2024 - DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
0
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
https://www.zacks.com/stock/news/2331539/atha-stock-tanks-as-alzheimer-s-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2331539
Sep 04, 2024 - Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
0
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
https://www.fool.com/investing/2024/08/31/these-3-factors-could-make-eli-lilly-stock-better-/?source=iedfolrf0000001
Aug 31, 2024 - This competitive showdown just saw one of the players hit a couple of bumps.
0
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
https://www.zacks.com/stock/news/2325629/why-biogen-inc-biib-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2325629
Aug 22, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
https://www.zacks.com/stock/news/2321929/is-eli-lilly-lly-a-buy-post-stellar-q2-earnings-raised-view?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2321929
Aug 14, 2024 - Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.
0
3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View
https://www.zacks.com/stock/news/2321388/3-big-drug-stocks-to-watch-on-raised-2024-earnings-sales-view?cid=CS-ZC-FT-analyst_blog|investment_ideas-2321388
Aug 13, 2024 - Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.
0
Page 1>